Italian guidelines for antiretroviral therapy in children with human immunodeficiency virus-type 1 infection. Italian Register for HIV Infection in Children.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Italian guidelines for antiretroviral therapy in children with human immunodeficiency virus-type 1 infection. Italian Register for HIV Infection in Children.

Acta Paediatr. 1999 Feb;88(2):228-32. Unique Identifier : AIDSLINE MED/99200284

Abstract: Human immunodeficiency virus-type 1 (HIV-1) infection and its treatment are peculiar in children. Adherence and compliance must be carefully taken into account before initiating or changing therapy and in the choice of drugs. Even in the absence of paediatric-specific trial results and notwithstanding drug-labelling notations, all antiretroviral drugs should be used when indicated. A combined therapy is compulsory. Therapy is highly recommended in category C or category 3 and recommended in category B children. Indications in categories N1, N2, A1 or A2 are limited. A triple association is recommended in category C or category 3 children or in those with a high viral load, when compliance is guaranteed. A step-down strategy is not advisable. Infants' treatment should be inserted into controlled studies. Therapy should be changed when serious side effects or poor tolerance (choose drugs with a different toxicity and greater tolerance), poor compliance (individualize the motives) or treatment failure (evaluate progression and adherence) occurs.

Keywords: GUIDELINE JOURNAL ARTICLE PRACTICE GUIDELINE Anti-HIV Agents/*THERAPEUTIC USE Child, Preschool Human HIV Infections/*DRUG THERAPY/VIROLOGY *HIV-1 Infant Infant, Newborn Patient Compliance Support, Non-U.S. Gov't Treatment Failure
990830
A9980931

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .